4F-MDMB-BINACA Wikipedia - Revision history

ISZCindy643869 at 19:15, 28 May 2026

2026-05-28T19:15:29Z

AWASanora93465 at 19:15, 28 May 2026

2026-05-28T19:15:14Z

StarlaSaldana91 at 19:05, 28 May 2026

2026-05-28T19:05:44Z

HectorPopp3 at 06:48, 27 May 2026

2026-05-27T06:48:26Z

IanSalo763: Created page with "Our findings revealed that both victims consumed large amounts of alcohol preceding their deaths (blood alcohol concentrations (BAC) were 2.11 and 2.49 g/L, respectively). For..."

2026-05-27T03:33:33Z

Created page with "Our findings revealed that both victims consumed large amounts of alcohol preceding their deaths (blood alcohol concentrations (BAC) were 2.11 and 2.49 g/L, respectively). For..."

New page

Our findings revealed that both victims consumed large amounts of alcohol preceding their deaths (blood alcohol concentrations (BAC) were 2.11 and 2.49 g/L, respectively). Forensic autopsy of both victims was performed four days after the time of death following the Recommendation No.R (99)3 of the Council of Europe on medico-legal autopsies. Elegans demonstrated the ability to form all of the in-vivo metabolites and has the potential to be used as a complementary model to predict and characterize human metabolites, as well as identifying possible drug toxicities for emerging SCBs. Thus, identification of the relevant urinary markers was based primarily upon the prevalence of the in-vivo metabolites instead of the metabolites ranking that was based upon % peak area abundance ratio. Moreover, genetic makeup, physiological conditions (age, gender [https://cannabinoidsrc4f-adb.com/ cannabinoidsrc4f-adb.com] and ethnicity), environmental influences (diet) and pathological factors (liver diseases, diabetes, and obesity) would further complicate the metabolism of drugs. It should be noted that % peak area abundance ratios do not necessarily reflect absolute concentrations due to differences in ionization capacity and matrix effects bias for each metabolite. Victim B also brought "something resembling a drug" (unrecognizable by Witness A) from his cousin (Witness B) in a cigarette box and mixed this substance with their tobacco. The half-maximal effective concentration (EC50) of 4F-MDMB-BINACA is 5.69 nM (2.76–11.0 nM) on CB1, and 0.69 nM (0.30–1.56 nM) on CB2, in vitro half-life (t1/2) is 10.27 min . It is usually available as a powder, liquid (vapor fluid), or herbal plant mixtur Oxidation of 4′-hydroxybutyl moiety in B2 led to formation of 4′-carboxybutyl metabolite (B4) having a precursor ion of m/z 362, which was 14 Da higher than the m/z for B2 (loss of two hydrogen atoms with addition of a carbonyl group The same procedure was then applied to the mice once every day for 5 days. It was considered as coordination disturbance when mice fell from the test apparatus within 2 min. Mice that remained their position on the running apparatus at 10 rpm for at least 2 min were selected for further evaluation. Table of Conten Similarly, precursor ion identified at m/z 380 (B19/B21, B23/B25) was 16 Da higher than the 4F-MDMB-BINACA, indicating monohydroxylation at the butyl side chain (B19/B21) and indazole (B23/B25) moieties with product ions m/z 145 and 161, respectively. Metabolites identified at m/z 366 (B8, B9, B13), which was 16 Da higher than the 4F-MDMB-BINACA ester hydrolysis metabolite (B22), confirmed monohydroxylation upon ester hydrolysis. Death involving these drugs have been reported [5,6,7,8,9], and this raises public health and social concerns. Due to their similar physiological effects to the principal psychoactive component of cannabis, Δ9-tetrahydrocannabinol (THC), SCBs are gaining popularity and are often abused as recreational drugs. The fact that similar 4F-MDMB-BINACA and ethanol concentrations were detected in the postmortem blood samples of both victims suggests that both substances played a role in the fatal outcom When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-of-care DOA tests. In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC In the present study, we performed various methods based on animal behavioral testing including FOB test for general behavioral observation, rotarod test, locomotor activity test for motor function evaluation, and water-maze test for learning/memory evaluation. Known for its stability and consistent composition, this compound is frequently utilized by professionals seeking reliable materials for laboratory-based analytical studies. In this study, histopathological evaluation was performed to confirm the possibility of neurotoxicity of the tested substances by hematoxylin and eosin staining method from collected brain samples. In the present study, we evaluated the neurotoxicity of two synthetic cannabinoids (JWH-081 and JWH-210) through observation of various behavioral changes and analysis of histopathological changes using experimental mice with various doses (0.1, 1, 5 mg/kg). Selecting powder JWH-210 demands careful evaluation of purity, legality, and supplier credibility. Prices for research-grade JWH-210 vary significantly based on quantity, purity, and vendor complianc Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. It is illegal to sell, distribute, supply, transport or trade the pharmaceutical drug under the Psychoactive Substances Act 2016. The corresponding indole core analogue, 4F-MDMB-BICA (4F-MDMB-BUTICA), has also been widely sold as a designer drug by chemical providers on the internet, first being identified in May 2020. It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug since late 2018. 4F-MDMB-BINACA (also known as MDMB-4F-BINACA using systematic EMCDDA nomenclature or 4F-MDMB-BUTINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family. Fig.

← Older revision		Revision as of 19:15, 28 May 2026
Line 1:		Line 1:
−	~~Figure 1~~. ~~<br>Each training session lasted a maximum~~ of ~~10 min, and~~ the ~~rats could earn up~~ to ~~20 food pellets~~. ~~Thirty minutes prior~~ to the ~~training sessions, rats received an injection of either vehicle or Δ9-THC~~ and ~~were subsequently placed~~ in ~~the behavior-testing chambers, where food~~ (~~45-mg food pellets; Bio-Serve~~, ~~Frenchtown, NJ~~) ~~was available as a reinforcer~~ for ~~every ten responses (FR10) on a designated injection appropriate lever~~. ~~A houselight was centered over~~ the ~~hopper close to the ceiling and~~ was ~~illuminated only when the levers were active. Each dose range included doses that were without effect~~ to ~~those producing~~ at ~~least 50% depression compared to vehicle control~~. ~~Twenty-four male Sprague-Dawley rats~~ were ~~obtained from Envigo~~ (~~Houston, TX~~). ~~Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained~~ in ~~the University of North Texas Health Science Center~~ (~~UNTHSC) animal facility~~ for ~~two weeks prior to testin~~<br><br><br>~~In summary, JWH~~-~~210 Chemical Powder stands out as a high~~-~~quality research compound designed for professionals who demand accuracy~~, ~~consistency~~, ~~and reliability. This commitment to 5CL ADBA powder quality makes it a trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging~~, ~~every stage of the process is monitored to ensure compliance with laboratory-grade expectations. This makes it an ideal choice for laboratories that prioritize both efficiency~~ and ~~compliance with research standards.<br>Key Features and Specifications to Evaluate <br>Higher prices~~ often ~~reflect rigorous quality control rather than markup alone~~. ~~This compound is appropriate only for authorized professionals conducting lawful research or analysis~~. ~~For legitimate applications, only fully characterized, independently~~ tested ~~JWH~~-~~210 [https:~~/~~/cannabinoidsrc4f~~-~~adb~~.~~com/ 5CL ADBA powder] should be considered.<br>How to Choose Powder JWH~~-~~210 <br>When learning how to choose powder JWH~~-~~210, the most critical factor is verifying high chemical purity~~ (~~≥98%) from a reputable supplier with independent lab testing. We~~ also ~~demonstrated that JWH~~-~~210 administration resulted in the decrease of expression levels of T~~-~~cell activator including Cd3e~~, ~~Cd3g~~, ~~Cd74p31~~, and ~~Cd74p41, while JWH~~-~~030 increased Cd3g levels. JWH~~-~~210 (10 mg/kg~~, ~~3 days, i.p.~~) ~~is more likely to have cytotoxicity and reduce lymphoid organ weight than JWH-030 of ICR mice~~ in vivo~~. Users are expected~~ to ~~handle the compound in accordance with all applicable regulations and safety guidelines within~~ their jurisdiction. It is important to note that JWH-210 Chemical Powder is intended strictly for research and laboratory use only. Its reputation for purity and stability has contributed to its widespread use in controlled environments where precision is paramoun<br><br><br>~~All~~ of ~~the compounds tested~~ in ~~the present study depressed locomotor activity~~ as is ~~typical for other synthetic cannabinoids (see review~~ by ~~Wiley et al.~~, ~~2017~~). ~~Average horizontal activity counts/10 min as a function of time~~ (~~10 min bins~~) ~~and dose~~. ~~Depressant effects~~ of 1.~~33 mg/kg were observed within 10 min following administration~~ and ~~peak depressant~~ effects ~~were 5CL ADBA powder observed between 0–30 min~~. ~~Duration~~ of the ~~locomotor depression increased over dose from 30 min following 0.1 mg/kg~~ to ~~2.5 h following 1 mg/k~~<br><br>~~4. Drugs <br>Short~~-~~onset~~, ~~short~~-~~acting compounds have a greater abuse liability~~, and ~~long~~-~~acting compounds pose problems of long-acting adverse effects and interactions with other drugs.~~ The ~~duration of action~~ of the ~~synthetic cannabinoids tested using the 8-h protocol have varied widely~~, ~~with some producing a duration~~ of ~~action no longer than 1 h, others producing a duration of action between 1–2 h~~, and ~~others lasting more than 2 h~~. ~~There seems~~ to be ~~a trend of newer synthetic cannabinoids being more potent than earlier compounds~~. ~~All of~~ the ~~compounds tested~~ in the ~~present~~ study ~~depressed locomotor activity~~ as ~~is typical for other synthetic cannabinoids (see review by Wiley et al~~., ~~2017). Average horizontal activity counts/10 min as a function of time~~ (~~10 min bins~~) and ~~dose. Depressant effects~~ of ~~1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.~~<br>~~Michael B Gat~~<br><br>~~<br>A 30~~-~~min period, beginning when maximal depression~~ of ~~locomotor activity first appeared as~~ a ~~function~~ of ~~dose~~, ~~was used for analysis~~ of ~~dose~~-~~response data and calculation~~ of ~~ED50 values. During~~ test ~~sessions, both levers were active, such that ten consecutive responses~~ on ~~either lever led to 5CL ADBA powder reinforcement~~. ~~The substitution tests occurred only if~~ the ~~rats had achieved 85% injection~~-~~appropriate responding on the two prior training sessions~~.<br>The ~~locomotor activity assay was used to identify approximate~~ time ~~courses~~ and ~~dose ranges~~ of ~~psychoactive effects, which is useful for identifying parameters for drug discrimination experiments~~ and ~~are also predictive~~ of the ~~time course of~~ the ~~psychoactive effects in human users~~. The ~~purpose~~ of ~~the present study was~~ to ~~assess~~ the ~~abuse liability~~ of 5F-~~MDMB~~-~~PINACA, MDMB~~-~~CHIMICA, MDMB~~-~~FUBINACA, ADB~~-~~FUBINACA, and AMB~~-~~FUBINACA~~. ~~Since there is currently no robust measure of~~ the ~~reinforcing/rewarding effects of cannabinoids~~, ~~drug discrimination is currently~~ the ~~best model for assessing abuse liability~~ of ~~cannabinoids. The findings produce an apparent paradox, since CPP~~ and ~~self-administration predict with high reliability~~ the ~~likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human~~	+	After the incubation, mixture was centrifuged (18,000 x g, 20 °C) for 5 min and 0.5 μL of the supernatant was directly injected to the chromatographic system. In the next step, ammonium formate as salting agent was added to the mixture and incubated in a thermomixer (20 °C, 1200 rpm) for 15 min. After vortex-mixing, the mixture was allowed to stand 4F ADB at room temperature for 5 min. MS/MS experiments were performed in MRM (multiple reaction monitoring) mode with an isolation window of 0.4 m/z. The MS measurement was performed in positive ion mode (except for some acidic compounds such as barbiturates<br><br><br>These synthetic cannabinoids act 4F ADB directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit<br><br><br>Although there were reports on the metabolism of 4F-MDMB-BINACA using in-vivo and various in-vitro models, studies were either conducted using small in-vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons . The hepatic cell line HepG2 is often used as an initial screen as it is known to produce high reproducibility results with relatively stable enzyme concentration, although they are limited by the low-level expression of several metabolizing enzymes, including the cytochrome P450 (CYP) class of proteins [17, 18]. In-vitro metabolism studies are generally used to complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled human liver microsomes (HLM) have been frequently used to elucidate metabolism of SCBs [12,13,14,15,16]. Since most SCBs are found extensively in metabolized forms in urine, the identification of metabolites is of vital importance for forensic and clinical toxicologists. Identifying SCB intake and its correlating specific adverse effects require rapid elucidation of these SCBs. The proliferation of SCBs has become a global challenge as new compounds are rapidly introduced into the illegal drug market to evade existing drug law<br><br>Metabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans <br>The % peak area abundance ratio of metabolites detected in the urine samples are often affected by numerous factors such as drug intake behaviour (intake route, amount of drug and intake frequency), time from last drug intake and metabolic stability. This indicated that the phase I metabolism of 4F-MDMB-BINACA are unlikely to be affected significantly by polydrug intake. Oxidative defluorination with subsequent butanoic acid formation (B17) metabolite, the second major metabolite after monohydroxylation in the C. Ester hydrolysis with dehydrogenation formed in-vivo in this study was also reported among other indazole carboxamide type SCBs with tert-leucine methyl ester moieties such as 5F-MDMB-PINACA and MDMB-4en-PINACA [39, 40]. Similar to the in-vivo findings, 4F-MDMB-BINACA ester hydrolysis (B22) was the major metabolite for both HepG2 and HLM models, consistent with the known hydrolytic activity of CES reported<br><br><br>High resolution mass spectrometry such as LC-QTOF-MS allows the detection and identification of a broad spectrum of recreational drugs, including new psychoactive substances. A point-of-care drugs of abuse (DOA) test was initially performed on the urine of the patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep, Turkey 10 seconds before the onset of his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes. Combined with non-specific, transient symptoms, clinical recognition of SCRA intoxication is challenging .<br>Data availability <br>The intensity is plotted against the retention time for both chromatograms, demonstrating the [https://cannabinoidsrc4f-adb.com/ 4F ADB] presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. LC-QTOF-MS Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) in the Vape Liquid used by the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine and ADB-BUTINACA (Fig. 1). Because the point-of-care DOA test is generally not able to detect synthetic recreational drug substances, the liquid of the e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) on the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom

← Older revision		Revision as of 19:15, 28 May 2026
Line 1:		Line 1:
−	Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those of Δ9-THC (Bannister and Connor, 2018), and MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al.~~, 2018~~<br>~~<br><br>Inclusion in an NLM database does not imply endorsement~~ of, ~~or agreement with,~~ the ~~contents by NLM or the National Institutes of Health~~. ~~It is illegal~~ to ~~sell~~, ~~distribute, supply, transport~~ or ~~trade~~ the ~~pharmaceutical drug under the Psychoactive Substances Act 2016. The corresponding indole core analogue~~, ~~4F-MDMB-BICA~~ (4F-~~MDMB~~-~~BUTICA~~)~~, has also been widely sold~~ as a ~~designer drug by chemical providers~~ on the ~~internet, first being identified in May 2020~~. ~~It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug since late 2018~~. 4F-~~MDMB~~-~~BINACA~~ (~~also known as MDMB-4F-BINACA using systematic EMCDDA nomenclature or 4F-MDMB-BUTINACA~~) ~~is an indazole-based synthetic cannabinoid~~ from the ~~indazole-3-carboxamide family.~~<br>~~Fig.~~ <br><br>~~<br>After the incubation~~, ~~mixture was centrifuged (18~~,~~000 x g~~, ~~20 °C) for 5 min~~ and 0.~~5 μL of the supernatant was directly injected~~ to ~~the chromatographic system. In the next step, ammonium formate as salting agent was added to the mixture and incubated in~~ a ~~thermomixer (20 °C, 1200 rpm)~~ for ~~15 min~~. ~~After vortex-mixing~~, the ~~mixture was allowed~~ to ~~stand cannabinoidsrc4f~~-~~adb~~.~~com website at room temperature~~ for ~~5 min. MS/MS experiments were performed in MRM (multiple reaction monitoring) mode~~ with ~~an isolation window of 0~~.~~4 m/z. The MS measurement was performed in positive ion mode (except for some acidic compounds such as barbiturates~~<br><br>~~<br>Effects of individual doses were compared to the vehicle~~ control ~~value using a priori contrasts~~. ~~Response-rate data were analyzed by one-way repeated-measure~~ analysis ~~of variance~~. ~~Percent drug~~-~~appropriate responding was shown only if at~~ cannabinoidsrc4f-adb.com ~~website least three rats completed the first fixed ratio, whereas all rats are shown for the response rate dat~~<br><br>~~Legal status <br>~~JWH-210 ~~Chemical Powder offers~~ a ~~reliable solution for laboratories seeking a compound that meets stringent requirements~~. ~~Researchers often require compounds~~ that ~~are consistent~~ and ~~dependable~~, ~~and this product delivers on both fronts~~. ~~Whether used in small~~-~~scale experiments or larger research projects~~, the compound ~~maintains its integrity under recommended storage conditions~~. ~~This ensures ease of handling~~ and ~~precise measurement during~~ laboratory use. ~~Each batch undergoes detailed verification to ensure~~ purity~~, consistency,~~ and ~~accuracy, making it suitable for~~ controlled ~~experimental~~ environments~~. This study was supported by a grant (13181MFDS654) of the National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Republic of Kore~~<br><br><br>~~Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times~~ of ~~peak effect. Previous studies have demonstrated that these~~ compounds ~~have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at~~ the ~~CB1 receptor. Tremors were not observed following AMB-FUBINACA during the drug discrimination~~ study~~, but the maximum dose tested was only 0.1 mg/kg, which~~ is ~~10-fold lower than the dose that produced tremors in the mice. AMB-FUBINACA has been implicated in severe adverse effects in recreational users~~ (~~Adams~~ et al., 2017~~; Hamilton et al~~.~~, 2017~~)~~, which suggests that the range between behaviorally active~~ and ~~toxic doses~~ of ~~AMB-FUBINACA is narrow~~. ~~Following that line of reasoning, it should also be noted that some of the more recent compounds produced non-linear dose-effect curves~~ and ~~one compound produced an inverted U-shaped dose-effect, such that intermediate dose fully substituted, but higher doses did not (Gatch and Forster, 2018)~~. ~~All~~ of the ~~compounds identified as available on the recreational market and submitted to our laboratory by the US Drug Enforcement Agency for testing have fully substituted at some~~ dose ~~(Gatch and Forster 2014, 2015, 2016, 2018); however; it is important~~ to ~~note that not all structural congeners are active (Wiley et al~~.~~, 2012~~<br><br><br>~~Product ions detected at m/z 302~~, ~~217~~, and ~~145 (B2) confirmed that tert~~-~~leucine and indazole moieties remained unchanged, leading to the structure elucidation~~ of ~~a hydroxy~~-~~functional group at the 4-position of the butyl side chain by oxidative defluorination~~. The ~~product ion m/z 336 (loss~~ of ~~methyl ester moiety) further confirmed~~ the ~~presence~~ of ~~dihydroxylated metabolites. The precursor ion, m/z 364 (B14~~, ~~B5/B6) had~~ a ~~loss~~ of 2 ~~Da from m/z 366 indicated further dehydrogenation~~ of ~~the ester hydrolysis plus monohydroxylated metabolites~~. ~~The presence~~ of the ~~product ion m/z 320, likely formed from a loss of carbon dioxide, indicated monohydroxylation at~~ the ~~tert-leucine in B8~~ (~~m/z 219)~~, ~~butyl side chain in B9 (m/z 145) and indazole moiety in B13 (m/z 161~~). ~~The precursor ion, m~~/~~z 350 showed~~ a ~~loss~~ of ~~14 Da explaining the hydrolysis~~ of ~~methyl ester from 4F-MDMB-BINACA~~.<br>~~Fig. 2.~~ <br>~~The precursor ion m/z 396 (B10, B12/B15) was 32 Da higher than the parent drug, 4F~~-~~MDMB-BINACA~~, ~~suggesting the addition~~ of ~~two hydroxy groups. All the below explanations~~ for ~~transformations into metabolites are based on the~~ data ~~shown in Fig~~. ~~Metabolites~~ were ~~identified according~~ to ~~their precursor ions, product ions, and fragmentation patterns (Fig~~. ~~1). Traditional in~~-~~vivo metabolism studies to generate human metabolites of drugs relied heavily~~ on the ~~use~~ of ~~whole animal model systems~~, which ~~are expensive, limited by~~ drug ~~administration amount, influenced by species variation~~ and ~~faced by many ethical issues. Eight in-vivo metabolites tentatively identified were mainly products~~ of ester hydrolysis with or without additional dehydrogenation, N-dealkylation, monohydroxylation and oxidative defluorination with further oxidation to butanoic acid.<br>Fig. 1. <br>This outcome was anticipated since CES-mediated hydrolysis is commonly cannabinoidsrc4f-adb.com [https://cannabinoidsrc4f-adb.com/ cannabinoidsrc4f-adb.com website] reported as the ~~major metabolic pathway among~~ the SCBs impacting the terminal ester group . Glucosides and sulfate metabolites have been reported with other SCBs where C. From these three samples, sample 2 contained only an ester hydrolysis metabolite (m/z 350). Both ester hydrolysis followed by oxidative defluorination to butanoic acid (B4, m/z 362) and monohydroxylation at tert-leucine moiety (B8, m/z 366) metabolites were found in ~~16/20 urine samples (Table 2). A In-vitro metabolites observed in common among respective seven most abundant metabolites in b C~~. The ~~product ion detected at m/z 235, indicating loss~~ of ~~sulfate, confirmed~~ the ~~identity~~ of ~~the sulfation metabolite.<br>Fungus C. elegans <br>Methyl (2S)~~-~~2-([1-(4-fluorobutyl)-1H-indazole-3~~-~~carbonyl]amino)-3~~,~~3-dimethylbutanoate (4F-~~MDMB-~~BINACA~~, ~~4F-~~MDMB-~~BUTINACA or 4F~~-~~ADB)~~, ~~found in numerous SCB product seizures, has been reported by various law enforcement since 2018~~ . ~~However, most~~ of the ~~SCBs are full agonists at CB1 and CB2 receptors~~, ~~having a higher risk~~ of ~~undesirable side effects when compared to THC which is~~ a ~~partial agonist . Synthetic~~ cannabinoids ~~(SCBs)~~ are ~~agonists at cannabinoid receptor type 1 (CB1) and type 2 (CB2), where they elicit their main effect~~	+	Figure 1. <br>Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin<br><br><br>In summary, JWH-210 Chemical Powder stands out as a high-quality research compound designed for professionals who demand accuracy, consistency, and reliability. This commitment to 5CL ADBA powder quality makes it a trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging, every stage of the process is monitored to ensure compliance with laboratory-grade expectations. This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards.<br>Key Features and Specifications to Evaluate <br>Higher prices often reflect rigorous quality control rather than markup alone. This compound is appropriate only for authorized professionals conducting lawful research or analysis. For legitimate applications, only fully characterized, independently tested JWH-210 [https://cannabinoidsrc4f-adb.com/ 5CL ADBA powder] should be considered.<br>How to Choose Powder JWH-210 <br>When learning how to choose powder JWH-210, the most critical factor is verifying high chemical purity (≥98%) from a reputable supplier with independent lab testing. We also demonstrated that JWH-210 administration resulted in the decrease of expression levels of T-cell activator including Cd3e, Cd3g, Cd74p31, and Cd74p41, while JWH-030 increased Cd3g levels. JWH-210 (10 mg/kg, 3 days, i.p.) is more likely to have cytotoxicity and reduce lymphoid organ weight than JWH-030 of ICR mice in vivo. Users are expected to handle the compound in accordance with all applicable regulations and safety guidelines within their jurisdiction. It is important to note that JWH-210 Chemical Powder is intended strictly for research and laboratory use only. Its reputation for purity and stability has contributed to its widespread use in controlled environments where precision is paramoun<br><br><br>All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were 5CL ADBA powder observed between 0–30 min. Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/k<br><br>4. Drugs <br>Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.<br>Michael B Gat<br><br><br>A 30-min period, beginning when maximal depression of locomotor activity first appeared as a function of dose, was used for analysis of dose-response data and calculation of ED50 values. During test sessions, both levers were active, such that ten consecutive responses on either lever led to 5CL ADBA powder reinforcement. The substitution tests occurred only if the rats had achieved 85% injection-appropriate responding on the two prior training sessions.<br>The locomotor activity assay was used to identify approximate time courses and dose ranges of psychoactive effects, which is useful for identifying parameters for drug discrimination experiments and are also predictive of the time course of the psychoactive effects in human users. The purpose of the present study was to assess the abuse liability of 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA. Since there is currently no robust measure of the reinforcing/rewarding effects of cannabinoids, drug discrimination is currently the best model for assessing abuse liability of cannabinoids. The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human

← Older revision		Revision as of 19:05, 28 May 2026
Line 1:		Line 1:
−	~~During the death scene examination~~, ~~multiple cigarette butts without filters were found in an ashtray; also found were alcohol bottles~~, ~~an unopened box of nebivolol~~-~~containing drug~~, ~~and 18 g of unrecognizable herbal residue in a cigarette bo~~<br><br><br>~~All~~ of the ~~compounds tested in~~ the ~~present study depressed locomotor activity as~~ is ~~typical for other synthetic cannabinoids~~ (~~see review~~ by ~~Wiley et al.~~, ~~2017)~~. ~~Average horizontal activity counts/10 min~~ as a ~~function of time~~ (10 min ~~bins)~~ and ~~dose~~. ~~Depressant effects~~ of 1.~~33 mg/kg were observed within 10~~ min ~~following administration and peak depressant effects were~~ adb ~~butinaca observed between 0–30~~ min. ~~Duration~~ of ~~the locomotor depression increased over dose from 30 min following~~ 0.~~1 mg~~/~~kg to 2~~.~~5 h following 1 mg/k~~<br><br><br>Effects of individual doses were compared to the vehicle control value using a priori contrasts. Response-rate data were analyzed by one-way repeated-measure analysis of variance. Percent drug-appropriate responding was shown only if at adb ~~butinaca~~ least three rats completed the first fixed ratio, whereas all rats are shown for the response rate dat<br><br><br>~~The current study indicates~~ that ~~the test~~ compounds ~~produce locomotor depression similar to~~ that ~~of Δ9~~-~~THC~~, ~~and fully substitute for~~ the ~~discriminative stimulus effects~~ of ~~Δ9-THC~~. ~~In summary~~, ~~these 5F-MDMB-PINACA~~, ~~MDMB-CHIMICA~~, ~~MDMB-FUBINACA~~, ~~ADB-FUBINACA~~, and ~~AMB~~-~~FUBINACA~~ have similar abuse liability ~~as Δ9-tetrahydrocannabinol~~ and ~~should be controlled in a similar fashion. Much of~~ the ~~in vivo [https://cannabinoidsrc4f-adb~~.~~com/ adb butinaca] testing of the synthetic cannabinoid compounds have been pre~~-~~clinical studies focused on their cannabinoid-like effects or like~~ the ~~present~~ study, ~~focused on their abuse liability~~. ~~There~~ is ~~indication~~ that ~~at least some of~~ the ~~first~~-~~generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2~~ (~~Wiley~~ et al., ~~2016~~), and a compound ~~from the present study, 5F~~-~~MDMB~~-~~PINACA~~, ~~was found~~ to ~~activate midbrain dopamine neurons~~, ~~but~~ not ~~serotonin neurons~~ (~~Asaoka~~ et al., ~~2016~~<br><br><br>~~As synthetic cannabinoid receptor agonists~~ (~~SCRA~~) ~~are gaining popularity globally~~, ~~clinicians have~~ to ~~understand that intoxication caused by vaping SCRA is not detected~~ by ~~commonly available tests~~. ~~He confirmed that he had been vaping an electronic cigarette~~ (~~e-cigarette~~) ~~earlier that day just before~~ the ~~onset~~ of ~~his symptoms~~. ~~Metabolic acidosis~~ (~~1/3~~, 0/7) ~~and respiratory acidosis~~ (1/3, 0/7)~~, All 10 patients recovered with supportive care, including intubation~~ and ~~ventilation for one case~~. ~~In 3 cases ADB-BUTINACA was~~ the ~~only substance detected, while in seven other substances~~ of ~~misuse were also detected including other SCRA, opioids, benzodiazepines cocaine and pregabali~~<br><br>~~<br>Although there were reports on~~ the ~~metabolism of~~ 4F-MDMB-BINACA ~~using in-vivo and various in-vitro models~~, ~~studies were either conducted using small~~ in~~-vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons~~ . ~~The hepatic cell line HepG2 is often used as an initial screen as it is known~~ to ~~produce high reproducibility results with relatively stable enzyme concentration~~, ~~although they are limited by the low-level expression of several metabolizing enzymes~~, ~~including the cytochrome P450~~ (~~CYP~~) ~~class of proteins [17, 18]~~. In-~~vitro~~ metabolism studies ~~are generally used~~ to ~~complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled~~ human ~~liver microsomes (HLM) have been frequently used to elucidate metabolism~~ of ~~SCBs [12~~,13,14,~~15,16]~~. ~~Since most SCBs are found extensively~~ in ~~metabolized forms in urine, the identification of~~ metabolites is of ~~vital importance for forensic~~ and clinical toxicologists. Identifying SCB intake and its correlating specific adverse effects require rapid elucidation of these SCBs. The proliferation of SCBs has become a global challenge as new compounds are rapidly introduced into the illegal drug market to ~~evade existing drug laws~~.<br>Fig. <br>~~<br><br>Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those adb butinaca of Δ9~~-~~THC (Bannister and Connor, 2018), and MDMB~~-~~FUBINACA fully substituted for Δ9~~-~~THC (Gamage et al~~.~~, 2018)~~. ~~The chemical structures of~~ the ~~recent synthetic cannabinoids are unlike that of Δ9-THC, but are largely based on~~ the ~~structure of older synthetic cannabinoids that are known to~~ have ~~substantial abuse liability~~ (~~Fig~~. 1)~~. All 5 compounds decreased locomotor activity~~ and ~~produced discriminative stimulus effects similar to those of Δ9~~-~~THC~~, ~~which suggests they may have abuse liability similar to that of Δ9-THC~~. ~~Subsequent testing identified 5F~~-~~ADB to have been present~~ in ~~a total of ten people who had died from unexplained drug overdoses~~ in ~~Japan between September 2014 and December 2014~~. ~~AMB-FUBINACA produced tremors and may be~~ of ~~increased risk in human recreational users~~.<br>~~Michael B Gatch~~ <br>~~These findings are in agreement with earlier studies showing the synthetic cannabinoids substitute for the discriminative stimulus effects of Δ9~~-~~THC~~ (~~see review by Wiley et al.~~, ~~2017~~)~~. Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time of peak depression~~ in ~~the locomotor activity assay in mice~~. ~~As mentioned previously~~, ~~short-onset compounds have a greater abuse liability; further, compounds that have fewer adverse effects while they are active are likely to be preferred. All five~~ of the ~~compounds in the present study fully substituted with a pretreatment time of 15 min~~, ~~suggesting~~ a ~~rapid onset~~ of ~~the discriminative stimulus~~ effects. ~~All of the cathinones fully substituted for the discriminative stimulus effects of Δ9-tetrahydrocannabinol~~ (~~≥80% drug-appropriate responding~~)~~. Because response suppression may compromise stimulus control~~, ~~rats failing to complete at least ten responses during the test session were excluded from the analysis of the discriminative stimulus effects of that dose of test compoun~~	+	Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those of Δ9-THC (Bannister and Connor, 2018), and MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al., 2018<br><br><br>Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. It is illegal to sell, distribute, supply, transport or trade the pharmaceutical drug under the Psychoactive Substances Act 2016. The corresponding indole core analogue, 4F-MDMB-BICA (4F-MDMB-BUTICA), has also been widely sold as a designer drug by chemical providers on the internet, first being identified in May 2020. It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug since late 2018. 4F-MDMB-BINACA (also known as MDMB-4F-BINACA using systematic EMCDDA nomenclature or 4F-MDMB-BUTINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family.<br>Fig. <br><br><br>After the incubation, mixture was centrifuged (18,000 x g, 20 °C) for 5 min and 0.5 μL of the supernatant was directly injected to the chromatographic system. In the next step, ammonium formate as salting agent was added to the mixture and incubated in a thermomixer (20 °C, 1200 rpm) for 15 min. After vortex-mixing, the mixture was allowed to stand cannabinoidsrc4f-adb.com website at room temperature for 5 min. MS/MS experiments were performed in MRM (multiple reaction monitoring) mode with an isolation window of 0.4 m/z. The MS measurement was performed in positive ion mode (except for some acidic compounds such as barbiturates<br><br><br>Effects of individual doses were compared to the vehicle control value using a priori contrasts. Response-rate data were analyzed by one-way repeated-measure analysis of variance. Percent drug-appropriate responding was shown only if at cannabinoidsrc4f-adb.com website least three rats completed the first fixed ratio, whereas all rats are shown for the response rate dat<br><br>Legal status <br>JWH-210 Chemical Powder offers a reliable solution for laboratories seeking a compound that meets stringent requirements. Researchers often require compounds that are consistent and dependable, and this product delivers on both fronts. Whether used in small-scale experiments or larger research projects, the compound maintains its integrity under recommended storage conditions. This ensures ease of handling and precise measurement during laboratory use. Each batch undergoes detailed verification to ensure purity, consistency, and accuracy, making it suitable for controlled experimental environments. This study was supported by a grant (13181MFDS654) of the National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Republic of Kore<br><br><br>Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mice. AMB-FUBINACA has been implicated in severe adverse effects in recreational users (Adams et al., 2017; Hamilton et al., 2017), which suggests that the range between behaviorally active and toxic doses of AMB-FUBINACA is narrow. Following that line of reasoning, it should also be noted that some of the more recent compounds produced non-linear dose-effect curves and one compound produced an inverted U-shaped dose-effect, such that intermediate dose fully substituted, but higher doses did not (Gatch and Forster, 2018). All of the compounds identified as available on the recreational market and submitted to our laboratory by the US Drug Enforcement Agency for testing have fully substituted at some dose (Gatch and Forster 2014, 2015, 2016, 2018); however; it is important to note that not all structural congeners are active (Wiley et al., 2012<br><br><br>Product ions detected at m/z 302, 217, and 145 (B2) confirmed that tert-leucine and indazole moieties remained unchanged, leading to the structure elucidation of a hydroxy-functional group at the 4-position of the butyl side chain by oxidative defluorination. The product ion m/z 336 (loss of methyl ester moiety) further confirmed the presence of dihydroxylated metabolites. The precursor ion, m/z 364 (B14, B5/B6) had a loss of 2 Da from m/z 366 indicated further dehydrogenation of the ester hydrolysis plus monohydroxylated metabolites. The presence of the product ion m/z 320, likely formed from a loss of carbon dioxide, indicated monohydroxylation at the tert-leucine in B8 (m/z 219), butyl side chain in B9 (m/z 145) and indazole moiety in B13 (m/z 161). The precursor ion, m/z 350 showed a loss of 14 Da explaining the hydrolysis of methyl ester from 4F-MDMB-BINACA.<br>Fig. 2. <br>The precursor ion m/z 396 (B10, B12/B15) was 32 Da higher than the parent drug, 4F-MDMB-BINACA, suggesting the addition of two hydroxy groups. All the below explanations for transformations into metabolites are based on the data shown in Fig. Metabolites were identified according to their precursor ions, product ions, and fragmentation patterns (Fig. 1). Traditional in-vivo metabolism studies to generate human metabolites of drugs relied heavily on the use of whole animal model systems, which are expensive, limited by drug administration amount, influenced by species variation and faced by many ethical issues. Eight in-vivo metabolites tentatively identified were mainly products of ester hydrolysis with or without additional dehydrogenation, N-dealkylation, monohydroxylation and oxidative defluorination with further oxidation to butanoic acid.<br>Fig. 1. <br>This outcome was anticipated since CES-mediated hydrolysis is commonly cannabinoidsrc4f-adb.com [https://cannabinoidsrc4f-adb.com/ cannabinoidsrc4f-adb.com website] reported as the major metabolic pathway among the SCBs impacting the terminal ester group . Glucosides and sulfate metabolites have been reported with other SCBs where C. From these three samples, sample 2 contained only an ester hydrolysis metabolite (m/z 350). Both ester hydrolysis followed by oxidative defluorination to butanoic acid (B4, m/z 362) and monohydroxylation at tert-leucine moiety (B8, m/z 366) metabolites were found in 16/20 urine samples (Table 2). A In-vitro metabolites observed in common among respective seven most abundant metabolites in b C. The product ion detected at m/z 235, indicating loss of sulfate, confirmed the identity of the sulfation metabolite.<br>Fungus C. elegans <br>Methyl (2S)-2-([1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino)-3,3-dimethylbutanoate (4F-MDMB-BINACA, 4F-MDMB-BUTINACA or 4F-ADB), found in numerous SCB product seizures, has been reported by various law enforcement since 2018 . However, most of the SCBs are full agonists at CB1 and CB2 receptors, having a higher risk of undesirable side effects when compared to THC which is a partial agonist . Synthetic cannabinoids (SCBs) are agonists at cannabinoid receptor type 1 (CB1) and type 2 (CB2), where they elicit their main effect

← Older revision		Revision as of 06:48, 27 May 2026
Line 1:		Line 1:
−	~~Our findings revealed that both victims consumed large amounts~~ of ~~alcohol preceding their deaths~~ (~~blood alcohol concentrations~~ (~~BAC~~) ~~were 2~~.~~11 and 2~~.~~49 g~~/~~L, respectively)~~. ~~Forensic autopsy~~ of ~~both victims was performed four days after~~ the ~~time of death~~ following ~~the Recommendation No~~.~~R (99)3~~ of the ~~Council~~ of ~~Europe on medico~~-~~legal autopsies. Elegans demonstrated~~ the ~~ability to form~~ all of the ~~in-vivo metabolites and has~~ the ~~potential~~ to ~~be used as a complementary model to predict~~ and ~~characterize human metabolites, as well as identifying possible drug toxicities~~ for ~~emerging SCBs. Thus, identification of~~ the ~~relevant urinary markers was based primarily upon the prevalence~~ of ~~the in~~-~~vivo metabolites instead of the metabolites ranking that was based upon % peak area abundance ratio~~. ~~Moreover~~, ~~genetic makeup~~, ~~physiological conditions (age~~, ~~gender~~ [https://cannabinoidsrc4f-adb.com/ ~~cannabinoidsrc4f-~~adb~~.com~~] ~~and ethnicity)~~, ~~environmental influences (diet)~~ and ~~pathological factors~~ (~~liver diseases~~, ~~diabetes~~, and obesity) would further complicate the metabolism of drugs. It should be noted that % peak area abundance ratios do not necessarily reflect absolute concentrations due to differences in ionization capacity and matrix effects bias for each metabolite.<br>Victim B also brought "something resembling a ~~drug" (unrecognizable by Witness A)~~ from ~~his cousin (Witness B) in a cigarette box and mixed this substance with their tobacco. The half-maximal effective concentration (EC50) of 4F~~-MDMB-~~BINACA is 5.69 nM (2.76–11.0 nM) on CB1~~, ~~and 0.69 nM (0.30–1.56 nM) on CB2~~, ~~in vitro half-life~~ (~~t1/2) is 10.27 min~~ . ~~It is usually available as a powder~~, ~~liquid (vapor fluid), or herbal plant mixtur~~<br><br>~~Oxidation of 4′-hydroxybutyl moiety in B2 led~~ to ~~formation of 4′~~-~~carboxybutyl metabolite (B4~~) ~~having a precursor ion~~ of m/~~z 362~~, ~~which was 14 Da higher than the m~~/~~z for B2~~ (~~loss of two hydrogen atoms~~ with ~~addition of a carbonyl group<br><br><br>The same procedure was then applied to the mice once every day~~ for ~~5 days~~. It was ~~considered as coordination disturbance when mice fell from~~ the ~~test apparatus within 2 min. Mice that remained their position on the running apparatus at 10 rpm for at least 2 min~~ were ~~selected for further evaluation.~~<br>~~Table of Conten~~<br><br>~~<br>Similarly, precursor ion identified at m/z 380 (B19/B21, B23/B25) was 16 Da higher than~~ the 4F-MDMB-BINACA, ~~indicating monohydroxylation at the butyl side chain (B19/B21)~~ and ~~indazole (B23/B25) moieties~~ with ~~product ions m/z 145 and 161~~, ~~respectively. Metabolites identified at m/z 366 (B8~~, ~~B9, B13), which was 16 Da higher than~~ the ~~4F-MDMB-BINACA ester hydrolysis metabolite~~ (~~B22~~), ~~confirmed monohydroxylation upon ester hydrolysis~~. ~~Death involving~~ these ~~drugs~~ have been ~~reported~~ [5,6,7,8,9], and ~~this raises public health~~ and ~~social concerns. Due to their similar physiological~~ effects ~~to the principal psychoactive component~~ of ~~cannabis, Δ9-tetrahydrocannabinol (THC),~~ SCBs ~~are gaining popularity and are often abused as recreational drugs~~. The ~~fact that similar 4F-MDMB-BINACA and ethanol concentrations were detected in the postmortem blood samples~~ of ~~both victims suggests that both substances played~~ a ~~role in~~ the ~~fatal outcom~~<br><br><br>When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-of-care DOA tests. ~~In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC~~<br><br><br>~~In the present study~~, ~~we performed various methods based on animal behavioral testing including FOB test for general behavioral observation, rotarod test, locomotor activity test for motor function evaluation~~, and ~~water~~-~~maze test~~ for ~~learning/memory evaluation~~. ~~Known for its stability and consistent composition~~, ~~this compound is frequently utilized by professionals seeking reliable materials for laboratory-based analytical studies~~. ~~In this study, histopathological evaluation was performed to confirm~~ the ~~possibility~~ of ~~neurotoxicity of the tested substances by hematoxylin and eosin staining method from collected brain samples. In the present study~~, ~~we evaluated~~ the ~~neurotoxicity~~ of ~~two~~ synthetic cannabinoids (~~JWH-081 and JWH-210~~) ~~through observation of various behavioral changes~~ and ~~analysis~~ of ~~histopathological changes using experimental mice with various doses (0.1~~, ~~1, 5 mg/kg)~~. ~~Selecting powder JWH~~-~~210 demands careful evaluation~~ of ~~purity, legality,~~ and ~~supplier credibility~~. ~~Prices for research-grade JWH~~-~~210 vary significantly based on quantity, purity,~~ and ~~vendor complianc~~<br><br>~~<br>Inclusion~~ in ~~an NLM database does not imply endorsement of, or~~ agreement with, the ~~contents by NLM or~~ the ~~National Institutes~~ of ~~Health~~. ~~It is illegal to sell~~, ~~distribute, supply, transport or trade~~ the ~~pharmaceutical~~ drug ~~under~~ the ~~Psychoactive Substances Act 2016~~. ~~The corresponding indole core analogue~~, 4F-~~MDMB-BICA (4F-MDMB-BUTICA), has also been widely sold as~~ a ~~designer drug by chemical providers on the internet~~, ~~first being identified in May 2020~~. ~~It has been used as an active ingredient~~ in ~~synthetic cannabis products and sold as~~ a ~~designer drug since late 2018~~. 4F-~~MDMB-BINACA~~ (~~also known as MDMB-4F-BINACA using systematic EMCDDA nomenclature or 4F-MDMB~~-~~BUTINACA~~) ~~is an indazole-based synthetic cannabinoid~~ from the ~~indazole-3-carboxamide family.<br>Fig.~~	+	During the death scene examination, multiple cigarette butts without filters were found in an ashtray; also found were alcohol bottles, an unopened box of nebivolol-containing drug, and 18 g of unrecognizable herbal residue in a cigarette bo<br><br><br>All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were adb butinaca observed between 0–30 min. Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/k<br><br><br>Effects of individual doses were compared to the vehicle control value using a priori contrasts. Response-rate data were analyzed by one-way repeated-measure analysis of variance. Percent drug-appropriate responding was shown only if at adb butinaca least three rats completed the first fixed ratio, whereas all rats are shown for the response rate dat<br><br><br>The current study indicates that the test compounds produce locomotor depression similar to that of Δ9-THC, and fully substitute for the discriminative stimulus effects of Δ9-THC. In summary, these 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA have similar abuse liability as Δ9-tetrahydrocannabinol and should be controlled in a similar fashion. Much of the in vivo [https://cannabinoidsrc4f-adb.com/ adb butinaca] testing of the synthetic cannabinoid compounds have been pre-clinical studies focused on their cannabinoid-like effects or like the present study, focused on their abuse liability. There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016<br><br><br>As synthetic cannabinoid receptor agonists (SCRA) are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests. He confirmed that he had been vaping an electronic cigarette (e-cigarette) earlier that day just before the onset of his symptoms. Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3, 0/7), All 10 patients recovered with supportive care, including intubation and ventilation for one case. In 3 cases ADB-BUTINACA was the only substance detected, while in seven other substances of misuse were also detected including other SCRA, opioids, benzodiazepines cocaine and pregabali<br><br><br>Although there were reports on the metabolism of 4F-MDMB-BINACA using in-vivo and various in-vitro models, studies were either conducted using small in-vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons . The hepatic cell line HepG2 is often used as an initial screen as it is known to produce high reproducibility results with relatively stable enzyme concentration, although they are limited by the low-level expression of several metabolizing enzymes, including the cytochrome P450 (CYP) class of proteins [17, 18]. In-vitro metabolism studies are generally used to complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled human liver microsomes (HLM) have been frequently used to elucidate metabolism of SCBs [12,13,14,15,16]. Since most SCBs are found extensively in metabolized forms in urine, the identification of metabolites is of vital importance for forensic and clinical toxicologists. Identifying SCB intake and its correlating specific adverse effects require rapid elucidation of these SCBs. The proliferation of SCBs has become a global challenge as new compounds are rapidly introduced into the illegal drug market to evade existing drug laws.<br>Fig. <br><br><br>Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those adb butinaca of Δ9-THC (Bannister and Connor, 2018), and MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al., 2018). The chemical structures of the recent synthetic cannabinoids are unlike that of Δ9-THC, but are largely based on the structure of older synthetic cannabinoids that are known to have substantial abuse liability (Fig. 1). All 5 compounds decreased locomotor activity and produced discriminative stimulus effects similar to those of Δ9-THC, which suggests they may have abuse liability similar to that of Δ9-THC. Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014. AMB-FUBINACA produced tremors and may be of increased risk in human recreational users.<br>Michael B Gatch <br>These findings are in agreement with earlier studies showing the synthetic cannabinoids substitute for the discriminative stimulus effects of Δ9-THC (see review by Wiley et al., 2017). Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time of peak depression in the locomotor activity assay in mice. As mentioned previously, short-onset compounds have a greater abuse liability; further, compounds that have fewer adverse effects while they are active are likely to be preferred. All five of the compounds in the present study fully substituted with a pretreatment time of 15 min, suggesting a rapid onset of the discriminative stimulus effects. All of the cathinones fully substituted for the discriminative stimulus effects of Δ9-tetrahydrocannabinol (≥80% drug-appropriate responding). Because response suppression may compromise stimulus control, rats failing to complete at least ten responses during the test session were excluded from the analysis of the discriminative stimulus effects of that dose of test compoun